

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Wen Y. ChenApplication No./Patent No.: 7,201,905 Filed/Issue Date: April 10, 2007Entitled: Bi-Functional Cancer Treatment AgentsOncolix, Inc., a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title and interest in
(The extent (by percentage) of its ownership interest is _____%); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Wen Y. Chen & Thomas E. Wagner To: Greenville Hospital SystemThe document was recorded in the United States Patent and Trademark Office at
Reel 018796, Frame 0135, or for which a copy thereof is attached.2. From: Greenville Hospital System To: GHC Research Development CorporationThe document was recorded in the United States Patent and Trademark Office at
Reel 019640, Frame 0640, or for which a copy thereof is attached.
GHC Research Development3. From: Corporation To: Oncolix, Inc.The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Michael T. Redman

Printed or Typed Name

May 8, 2009

Date

President & CEO

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorldflow.com

STATE OF SOUTH CAROLINA

TRANSFER AND ASSIGNMENT

COUNTY OF GREENVILLE

THIS AGREEMENT (the "Transfer Agreement") is made as of this 24th day of January, 2007 between GHC RESEARCH DEVELOPMENT CORPORATION, South Carolina not-for-profit corporation ("RDC") and ONCOLIX, INC, a Delaware corporation ("Oncolix").

Whereas, RDC is the owner and holder to certain intellectual property related to the treatment of melanoma and breast cancer as described below (the "Transferred IP"); and

Whereas, RDC has determined it is in its interest to transfer the Transferred IP to Oncolix as provided herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the parties agree as follows:

1. Intellectual Property and Publication Rights.

- A. RDC hereby assigns and transfers all of its right, title and interest in any inventions, devices, procedures, techniques, information and/or know, whether patentable or not (including any existing patents and patent applications), with respect to the technologies and intellectual property described on Attachment A hereto.
- B. In consideration of this transfer and assignment, Oncolix will cause to be issued to RDC the following: One Million Two Hundred Thousand (1,200,000) shares of Oncolix common stock.
- C. As further consideration of the transfer, RDC (directly, indirectly through any governmental and non-profit organizations that it supports, and as provided in the agreement between Clemson University and the Greenville Hospital System dated May 28, 2003 pursuant to which Clemson University transferred its rights in the Transferred IP to Greenville Hospital System) shall enjoy the right to report all Transferred Intellectual Property as products which were developed through the scientific endeavors of the Oncology Research Institute of the Greenville Hospital System.

II. Reversion

In the event that Oncolix should: (1) dissolve, (2) declare bankruptcy or otherwise be placed in bankruptcy or other form of federal or state reorganization, (3) at any time during the six (6) years following the date hereof, in the reasonable judgment of RDC, cease to actively pursue the commercial development of any Transferred IP, or (4) within four (4) years of the date hereof, fail to secure independent, third party financing of a material portion of the development and commercialization costs associated with bringing any of the Transferred IP to market, then Oncolix shall assign, transfer and convey the Transferred IP which is not being so developed back to RDC or its assignee (s).

III. Other Agreements

- A. This Agreement is a part of the organization and capitalization of Oncolix, Inc. and as such shall be interpreted in conjunction with the organizational and other agreements which exists between the parties and dealing with the Tranferred IP.
- B. This Agreement may be executed in one or more counterparts.
- C. This Agreement does not render any party hereto the agent of another party for any purpose whatsoever.
- D. This Agreement shall be construed in accordance with the laws of the State of South Carolina.

In Witness whereof, the parties have executed this Agreement as of the date first above written.

GHC RESEARCH DEVELOPMENT CORPORATION

By: *James R. Yockey, III*

Its: *GRS VP, Director & Executive SDR VCS*

ONCOLIX, INC.

By: *Michael T. Red*

Its: *CEO*

GHS STATUS SHEET

Status

Title

GHS Reference No.

Client/Matter Number

FAMILY 1		HYBRID CELLS	
035879/0116	GHS-1US		US Patent issued: 6,849,451
035879/0136	GHS-1CA	2,396,992	Pending
035879/0137	GHS-1AU	36443/01	Granted AU 783931
035879/0138	GHS-1JP	2001-551182	Pending
035879/0139	GHS-1EP	1908591	Granted EP 1248836
035879/0140	GHS-1CN	1806229.6	Pending
035879/0172	GHS-1HK	3109345	Pending
035879/0194	GHS-1US-Div.	11/017,733	Pending
035879/0195	GHS-1EP-Div	1541675	Pending
035879/0199	GHS-1AT	1908591.9	Granted
035879/0200	GHS-1BE		Granted
035879/0201	GHS-1LI		Granted
035879/0202	GHS-1DE		Granted
035879/0203	GHS-1DK		Granted
035879/0204	GHS-1ES		Granted
035879/0205	GHS-1FR		Granted
035879/0206	GHS-1UK		Granted
035879/0207	GHS-1IE		Granted
035879/0208	GHS-1GR		Granted
035879/0209	GHS-1IT		Granted
035879/0210	GHS-1LU		Granted
035879/0211	GHS-1NL		Granted
035879/0212	GHS-1MC		Granted
035879/0213	GHS-1SE		Granted
035879/0243	GHS-1US-CIP		Multiple Excision case - filed
035879/0241	GHS-1US-CIP2		Neuroblastoma case - awaiting final comments from GHS

FAMILY 2		BI-FUNCTIONAL CANCER TREATMENT AGENTS	
035879/0120	GHS-2US	09/815,306	Notice of Allowance received
035879/0148	GHS-2CN	WO/2001/070985	Pending
035879/0149	GHS-2AU	2001249372	Abandoned
035879/0150	GHS-2CA	2,404,088	Abandoned
035879/0151	GHS-2EP	1268803	Abandoned
035879/0152	GHS-2JP	2001-569368	Pending

FAMILY 3		THERAPEUTIC PORE-FORMING PEPTIDES	
----------	--	-----------------------------------	--

GHS STRUCTURE SHEET

035879/0122	GHS-3US		US Patent issued: US 7,094,750
035879/0156	GHS-3EP	1933407.7	Granted
035879/0157	GHS-3CA	2,411,244	Pending
035879/0214	GHS-3US Div	11/123,182	Pending

FAMILY 4		LYTIC PEPTIDE PRODRUGS	
035879/0125	GHS-4US	09/938,623	Pending

FAMILY 7		USE OF ANTI-PROLACTIN AGENTS TREAT PROLIFERATIVE CONDITIONS	
035879/0134	GHS-7US	10/140,293	US Patent issued: 7,115,556
035879/0113	GHS-7CA	2,328,520	Pending
035879/0114	GHS-7EP	99921843	Intent to Grant Received
035879/0115	GHS-7JP	2000-547993	Pending
035879/0232	GHS-7US Div	11/498,962	Pending

FAMILY 12		MULTIMERIC LIGANDS WITH ENHANCED STABILITY	
035879/0162	GHS-12US	10/419,976	Pending
035879/0187	GHS-12EP	3726280.5	Pending
035879/0188	GHS-12CA	2,483,330	Pending

FAMILY 13		HUMAN PROLACTIN ANTAGONISTS- ANGIONESES INHIBITOR FUSION PROTEINS	
035879/0163	GHS-13US	10/449,609	Pending
035879/0153	GHS-13JP	2002-311540	Pending
035879/0191	GHS-13CA	2,487,291	Abandoned
035879/0192	GHS-13EP	3731479.6	Abandoned

FAMILY 16		COMBINATION THERAPY WITH HERCEPTIN & PROLACTIN	
035879/0196	GHS-16 US	11/073,927	Pending

FAMILY 19		ACETYLATED PROCYTOTOXINS	
035879/0215	GHS-19	11/131,443	Pending

GHS S1...US SHEET

FAMILY 22			PATIENT SPECIFIC HYBRID CELLS	
035879-0225	GHS-22 PCT			Pending